Amoeba SA (FR:ALMIB) has released an update.
Amoeba SA has reported a strategic shift from R&D to becoming a commercial and industrial entity by 2025, with a focus on biocontrol and cosmetics. The company has improved its operating result by over €1M in the first half of 2024 compared to the same period in 2023, reflecting cost optimization efforts in R&D, industrial deployment, and general expenses. Amoeba has submitted a marketing authorization application for biofungicide products in the US and is pursuing commercial partnerships following a positive skincare ingredient study.
For further insights into FR:ALMIB stock, check out TipRanks’ Stock Analysis page.
